IBBQ:NSD-Invesco Nasdaq Biotechnology ETF (USD)

ETF | Others |

Last Closing

USD 21.96

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Others

ETFs Containing IBBQ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.32% 38% F 49% F
Dividend Return 0.84% 24% F 17% F
Total Return 1.16% 28% F 47% F
Trailing 12 Months  
Capital Gain 15.58% 64% D 62% D
Dividend Return 1.25% 21% F 17% F
Total Return 16.83% 61% D- 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.21% 45% F 40% F
Dividend Return 0.51% 41% F 36% F
Total Return 0.30% 32% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 12.18% 51% F 86% B+
Risk Adjusted Return 4.18% 38% F 37% F
Market Capitalization 0.04B 54% F 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.